{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:52:21Z","timestamp":1793040741436,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacc.2025.09.1511","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:30:15Z","timestamp":1759210215000},"page":"2598-2612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy"],"prefix":"10.1016","volume":"86","author":[{"given":"Neal K.","family":"Lakdawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5683-6526","authenticated-orcid":false,"given":"Ray E.","family":"Hershberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry Mark","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ginns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Meder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4481-7867","authenticated-orcid":false,"given":"Jonathan W.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan R.","family":"Gimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Gerull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen L.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-1748","authenticated-orcid":false,"given":"Brian P.","family":"Halliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneeth","family":"Jarugula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonomi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saffie E.","family":"Mohran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu R.","family":"Anto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector M.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos L.","family":"del Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay M.","family":"Edelberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kurio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Maya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.09.1511_bib1","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1016\/j.jacc.2016.03.590","article-title":"The diagnosis and evaluation of dilated cardiomyopathy","volume":"67","author":"Japp","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib2","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1016\/j.jacc.2019.10.011","article-title":"Precision medicine in the management of dilated cardiomyopathy: JACC state-of-the-art review","volume":"74","author":"Fatkin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","article-title":"Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches","volume":"402","author":"Heymans","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1511_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","article-title":"Dilated cardiomyopathy: the complexity of a diverse genetic architecture","volume":"10","author":"Hershberger","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib5","article-title":"Eight-year survival analysis of patients with dilated cardiomyopathy: does treatment era affect prognosis?","volume":"17","author":"Kucera","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.jacc.2025.09.1511_bib6","first-page":"335","article-title":"Fifteen-year mortality and prognostic factors in patients with dilated cardiomyopathy: persistent standardized application of drug therapy and strengthened management may bring about encouraging change in an aging society","volume":"19","author":"Xu","year":"2022","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1511_bib8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jacc.2019.06.072","article-title":"Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy","volume":"74","author":"Gigli","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1161\/CIRCULATIONAHA.119.037661","article-title":"Reevaluating the genetic contribution of monogenic dilated cardiomyopathy","volume":"141","author":"Mazzarotto","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.1511_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1254272","article-title":"Diagnostic yield of genetic testing in a multinational heterogeneous cohort of 2088 DCM patients","volume":"10","author":"Heli\u00f6","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2025.09.1511_bib11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamacardio.2022.2455","article-title":"Assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing","volume":"7","author":"Dellefave-Castillo","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/CIRCGEN.120.003031","article-title":"Implications of genetic testing in dilated cardiomyopathy","volume":"13","author":"Verdonschot","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.jacc.2025.09.1511_bib13","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jacc.2021.08.039","article-title":"Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy","volume":"78","author":"Escobar-Lopez","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib14","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.ajhg.2023.08.003","article-title":"The penetrance of rare variants in cardiomyopathy-associated genes: a cross-sectional approach to estimating penetrance for secondary findings","volume":"110","author":"McGurk","year":"2023","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jacc.2025.09.1511_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.14740\/cr1680","article-title":"Prevalence of genetically associated dilated cardiomyopathy: a systematic literature review and meta-analysis","volume":"15","author":"Myers","year":"2024","journal-title":"Cardiol Res"},{"key":"10.1016\/j.jacc.2025.09.1511_bib16","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jacc.2022.07.023","article-title":"Natural history of MYH7-related dilated cardiomyopathy","volume":"80","author":"de Frutos","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1161\/CIRCGENETICS.112.962761","article-title":"Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy","volume":"5","author":"Lakdawala","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacc.2025.09.1511_bib18","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1074\/jbc.RA118.001938","article-title":"Dilated cardiomyopathy myosin mutants have reduced force-generating capacity","volume":"293","author":"Ujfalusi","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.09.1511_bib19","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCRESAHA.123.323988","article-title":"Titin-based force modulates cardiac thick and thin filaments","volume":"134","author":"Hessel","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2025.09.1511_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1126\/science.aaa5458","article-title":"HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy","volume":"349","author":"Hinson","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jacc.2025.09.1511_bib21","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/cvr\/cvaa316","article-title":"Titin-truncating mutations associated with dilated cardiomyopathy alter length-dependent activation and its modulation via phosphorylation","volume":"118","author":"Vikhorev","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2025.09.1511_bib22","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012514","article-title":"Role of targeted therapy in dilated cardiomyopathy: the challenging road toward a personalized approach","volume":"8","author":"Verdonschot","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.09.1511_bib23","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-019-0938-6","article-title":"Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion","volume":"18","author":"Packer","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib25","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/CIRCULATIONAHA.119.040514","article-title":"The serendipitous story of SGLT2 inhibitors in heart failure","volume":"139","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.1511_bib26","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1511_bib27","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.1511_bib28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2011.05.033","article-title":"Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study","volume":"58","author":"McNamara","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib29","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.1511_bib30","article-title":"MYK-491, a novel small-molecule cardiac myosin activator increases cardiac systolic function and preserves mechanical efficiency: pre-clinical in vivo and in vitro evidence","volume":"140","author":"Fernandes","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.1511_bib31","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/CIRCRESAHA.123.322629","article-title":"Danicamtiv increases myosin recruitment and alters cross-bridge cycling in cardiac muscle","volume":"133","author":"Kooiker","year":"2023","journal-title":"Circ Res"},{"issue":"Suppl","key":"10.1016\/j.jacc.2025.09.1511_bib32","first-page":"423","article-title":"MYK-491, a novel cardiac myosin activator, increases cardiac contractility in healthy volunteers","volume":"21","author":"Tamby","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.1511_bib33","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202513762","article-title":"Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil's in vivo cardiac effects","volume":"157","author":"Holmes","year":"2025","journal-title":"J Gen Physiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib34","first-page":"356","article-title":"The left atrial function index: a rhythm independent marker of atrial function","volume":"9","author":"Thomas","year":"2008","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.jacc.2025.09.1511_bib35","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008435","article-title":"Association of left atrial function index with atrial fibrillation and cardiovascular disease: the Framingham Offspring Study","volume":"7","author":"Sardana","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.09.1511_bib36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","article-title":"Reference ranges for NT-proBNP (N-terminal pro\u2013B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort","volume":"15","author":"Welsh","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.1511_bib37","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.3390\/jcm14124241","article-title":"The pathophysiology of cardiac troponin release and the various circulating cardiac troponin forms\u2014potential clinical implications","volume":"14","author":"Mair","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2025.09.1511_bib38","doi-asserted-by":"crossref","first-page":"H161","DOI":"10.1152\/ajpheart.00252.2024","article-title":"Differential effects of myosin activators on myocardial contractile function in nonfailing and failing human hearts","volume":"328","author":"Choi","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib39","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2515786122","article-title":"Danicamtiv reduces myosin's working stroke but activates the thin filament by accelerating actomyosin attachment","volume":"122","author":"Scott","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2025.09.1511_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.1511_bib41","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1113\/JP288913","article-title":"Danicamtiv increases cardiac mechanical efficiency","volume":"603","author":"Meehan","year":"2025","journal-title":"J Physiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib42","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.020860","article-title":"Danicamtiv enhances systolic function and Frank-Starling behavior at minimal diastolic cost in engineered human myocardium","volume":"10","author":"Shen","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.09.1511_bib43","doi-asserted-by":"crossref","first-page":"17314","DOI":"10.1074\/jbc.RA119.010217","article-title":"Dilated cardiomyopathy mutation in the converter domain of human cardiac myosin alters motor activity and response to omecamtiv mecarbil","volume":"294","author":"Tang","year":"2019","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacc.2025.09.1511_bib44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cardfail.2023.11.021","article-title":"Cardiac troponin and treatment effects of omecamtiv mecarbil: results from the GALACTIC-HF study","volume":"30","author":"Felker","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2025.09.1511_bib45","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.hfc.2017.12.004","article-title":"Genetic pathogenesis of hypertrophic and dilated cardiomyopathy","volume":"14","author":"Garfinkel","year":"2018","journal-title":"Heart Fail Clin"},{"key":"10.1016\/j.jacc.2025.09.1511_bib46","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1161\/CIRCULATIONAHA.105.567727","article-title":"Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure","volume":"113","author":"Davis","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.1511_bib47","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehs191","article-title":"Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section","volume":"33","author":"Januzzi","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.1511_bib48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.117.031560","article-title":"Prognostic value of high-sensitivity troponin T in chronic heart failure: an individual patient data meta-analysis","volume":"137","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.1511_bib49","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2025.09.1511_bib50","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study","volume":"67","author":"Teerlink","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.1511_bib51","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11897-023-00620-2","article-title":"Differentiating cardiac troponin levels during cardiac myosin inhibition or cardiac myosin activation treatments: drug effect or the canary in the coal mine?","volume":"20","author":"Lee","year":"2023","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacc.2025.09.1511_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2025-003215","article-title":"Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Aman","year":"2025","journal-title":"Open Heart"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725093738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725093738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:31:58Z","timestamp":1778545918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725093738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0735109725093738"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.09.1511","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.09.1511","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}